A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis

1994 ◽  
Vol 30 (4) ◽  
pp. 597-602 ◽  
Author(s):  
Matthew J. Stiller ◽  
Jerome L. Shupack ◽  
Clare Kenny ◽  
Lorrie Jondreau ◽  
David E. Cohen ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Atopic Dermatitis ◽  
Adjunctive Treatment ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Double Blind Placebo

scholarly journals A Multisite, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin for Treating Cocaine Dependence

2013 ◽  
Vol 70 (6) ◽  
pp. 630 ◽  
Author(s):  
Eugene C. Somoza ◽  
Douglas Winship ◽  
Charles W. Gorodetzky ◽  
Daniel Lewis ◽  
Domenic A. Ciraulo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cocaine Dependence ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Double Blind Placebo

scholarly journals Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
A. A. Harandi ◽  
R. Abolfazli ◽  
A. Hatemian ◽  
K. Ghragozlee ◽  
M. Ghaffar-Pour ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Ischemic Stroke ◽  
Treatment Group ◽  
Repeated Measures ◽  
Motor Recovery ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Stroke Treatment ◽  
Double Blind Placebo

Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke.Methods. This study was a double-blind, placebo-controlled clinical trial on 150 patients with a recent (less than 1 month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50 patients), 4 capsules 3 times a day, as an add-on to standard stroke treatment for 3 months.Results. Sex, age, elapsed time from stroke onset, and risk factors in the treatment group were not significantly different from placebo group at baseline (P>.05). Repeated measures analysis showed that Fugl-Meyer assessment was significantly higher in the treatment group during 12 weeks after stroke (P<.001). Good tolerability to treatment was shown, and adverse events were mild and transient.Conclusion. MLC601 showed better motor recovery than placebo and was safe on top of standard ischemic stroke medications especially in the severe and moderate cases.

Sumac as a novel adjunctive treatment in hypertension: a randomized, double-blind, placebo-controlled clinical trial

RSC Advances ◽  
2016 ◽  
Vol 6 (14) ◽  
pp. 11507-11512 ◽  
Author(s):  
Hamidreza Ardalani ◽  
Maryam Hassanpour Moghadam ◽  
Roja Rahimi ◽  
Jalal Soltani ◽  
Azadeh Mozayanimonfared ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Adjunctive Treatment ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Sumac; a novel adjunctive treatment in Blood Pressure.

scholarly journals Safety and efficacy of N-acetyl-cysteine for prophylaxis of ventilator-associated pneumonia: A randomized, double blind, placebo-controlled clinical trial

2018 ◽  
Vol 8 (1) ◽  
pp. 19 ◽  
Author(s):  
Ali Abdolrazaghnejad ◽  
Mojtaba Sharafkhah ◽  
Nader Zarinfar ◽  
Abolfazl Mohammadbeigi ◽  
Ali Massoudifar ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Ventilator Associated Pneumonia ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Double Blind Placebo ◽  
Acetyl Cysteine
Sign in / Sign up

Export Citation Format

Share Document